Leveraging Evolving Data to Inform Treatment in HR-Positive, HER2-Negative Advanced Breast Cancer

Join us for this dynamic, CME/MOC-certified symposium on the optimal treatment of patients with HR-positive, HER2-negative advanced breast cancer, featuring review and discussion of key clinical data and patient case studies by a panel of renowned breast cancer experts as well as a look ahead at promising agents in the setting of endocrine therapy–pretreated disease that may soon change practice.

Sign up now! Registration is complimentary.

Held in conjunction with SABCS® 2019


7:30 PM - 8:00 PM Dinner and Registration

8:00 PM - 8:10 PM Program Overview and IntroductionJoyce O’Shaughnessy, MD

8:10 PM - 8:35 PM CDK4/6 Inhibitors in the Management of HR+/HER2- MBCEric P. Winer, MD

8:35 PM - 9:00 PM Targeting the PI3K Pathway in HR+/HER2- MBCHope S. Rugo, MD

9:00 PM - 9:20 PM Promising Strategies on the Horizon for Endocrine Therapy–Pretreated HR+/HER2- MBCJoyce O’Shaughnessy, MD

9:20 PM - 9:30 PM Final Panel Discussion and Audience Question and Answer Session


Date / Time
Event Details


Program Director
Joyce O'Shaughnessy, MD

Celebrating Women Chair in Breast Cancer Research
Breast Cancer Research Program
Baylor University Medical Center
Texas Oncology
US Oncology Network
Dallas, Texas

Hope Rugo, MD

Clinical Professor of Medicine
UCSF Comprehensive Cancer Center
University of California, San Francisco
San Francisco, California

Eric P. Winer, MD

Director, Breast Oncology Center
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts

Goal Statement
The goal of this activity is to improve participants’ knowledge, confidence, and competence at selecting individualized treatment for patients with hormone receptor–positive breast cancer.

Target Audience 
This program is intended for physicians and other healthcare providers who care for patients with HR-positive/HER2-negative breast cancer.

Learning Objectives

  • Plan optimal treatment strategies for patients with HR+/HER2- advanced breast cancer based on available data, updated clinical guidelines, and expert recommendations
  • Appropriately integrate PI3K/Akt/mTOR and CDK4/6 targeted therapies into clinical practice for optimal personalized medicine for pre-, peri-, and postmenopausal patients with HR+/HER2- breast cancer
  • Manage adverse events associated with multidrug treatment regimens and recognize potential drug–drug interactions to improve patient outcomes
  • Discuss emerging research, the mechanisms of action, and the role of novel therapies and combinations in clinical investigation for patients with HR+/HER2- breast cancer


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation 

CCO designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

If you are interested in having us report ABIM MOC, please ensure the following information is provided within your CCO Member Profile:

Name - as registered with ABIM
Date of Birth (Month/Day)
Your ABIM ID number

Learners must complete the post-test with a passing score of 75% and provide additional documentation following the symposium.  

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.